Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer

British Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2004, Pages 576-585

  Goggin, Timothy ^a   Nguyen, Quyen T X ^a   Munafo, Alain ^a  

^a Serono International SA   (Switzerland)

Author keywords

Leukaemia inhibitory factor (LIF); NONMEM; Population pharmacokinetics

Indexed keywords

EMFILERMIN; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORGESTREL; NAFARELIN ACETATE; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT CYTOKINE; RECOMBINANT FOLLITROPIN; RECOMBINANT HUMAN LEUKEMIA INHIBITORY FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; POPULATION MODEL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL MODEL;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; EMBRYO TRANSFER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; MIDDLE AGED; MODELS, BIOLOGICAL; POSTMENOPAUSE; PROTEINS; RECOMBINANT PROTEINS;

EID: 2342448515     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02064.x     Document Type: Article

References (34)

1. Betzel C, Visanji M, Dauter Z, et al. Crystallization and preliminary X-ray analysis of leukemia inhibitory factor. FEBS Lett 1993; 336: 236-8.
2. Lass A, Weiser W, Munafo A, Loumaye E. Leukemia inhibitory factor in human reproduction. Fertil Steril 2001; 76: 1091-6.
3. Mathialagan N, Roberts RM. A role for cytokines in early pregnancy. Indian J Physiol Pharmacol 1994; 38: 153-62.
4. Stewart CL, Kaspar P, Brunet LJ, et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 1992; 359: 76-9.
5. Cheng JG, Rodriguez CI, Stewart CL. Control of uterine receptivity and embryo implantation by steroid hormone regulation of LIF production and LIF receptor activity: towards a molecular understanding of 'the window of implantation'. Rev Endocr Metab Disorders 2002; 3: 119-26.
6. Chen JR, Cheng JG, Shatzer T, Sewell L, Hernandez L, Stewart CL. Leukemia inhibitory factor can substitute for nidatory estrogen and is essential to inducing a receptive uterus for implantation but is not essential for subsequent embryogenesis. Endocrinol 2000; 141: 4365-72.
7. Fry RC. The effect of leukaemia inhibitory factor (LIF) on embryogenesis. Reprod Fertil Dev 1992; 4: 449-58.
8. Mitchell MH, Swanson RJ, Oehninger S. In vivo effect of leukemia inhibitory factor (LIF) and an anti-LIF polydonal antibody on murine embryo and fetal development following exposure at the time of transcervical blastocyst transfer. Biol Reprod 2002; 67: 460-4.
9. Vogiagis D, Salamonsen LA, Sandeman RM, Squires TJ, Butt AR, Fry RC. Effect of immunisation against leukaemia inhibitory factor on the establishment of pregnancy in sheep. Reprod Nutr Dev 1997; 37: 459-68.
10. Yue ZP, Yang ZM, Wei P, et al. Leukemia inhibitory factor, leukemia inhibitory factor receptor, and glycoprotein 130 in rhesus monkey uterus during menstrual cycle and early pregnancy. Biol Reprod 2000; 63: 508-12.
11. van Eijk MJ, Mandelbaum J, Salat-Baroux J, et al. Expression of leukaemia inhibitory factor receptor subunits LIFR beta and gp130 in human oocytes and preimplantation embryos. Molec Hum Reprod 1996; 2: 355-60.
12. Charnock-Jones DS, Sharkey AM, Fenwick P, Smith SK. Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. J Reprod Fertil 1994; 101: 421-6.
13. Nachtigall MJ, Kliman HJ, Feinberg RF, Olive DL, Engin O, Arici A. The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: a potential role in human implantation. J Clin Endocrinol Metab 1996; 81: 801-6.
14. Dunglison GF, Barlow DH, Sargent IL. Leukaemia inhibitory factor significantly enhances the blastocyst formation rates of human embryos cultured in serum-free medium. Hum Reprod 1996; 11: 191-6.
15. Spandorfer SD, Navarro J, Levy D, et al. Autologous endometrial coculture in patients with in vitro-fertilization (IVF) failure: correlations of outcome with leukemia inhibiting factor (LIF) production. Am J Reprod Immunol (Copenhagen) 2001; 46: 375-80.
16. Borini A, Bulletti C, Cattoli M, et al. Use of recombinant leukemia inhibitory factor in embryo implantation. Ann New York Acad Sci, 1997; 828: 157-61.
17. Vogiagis D, Marsh MM, Fry RC, Salamonsen LA. Leukaemia inhibitory factor in human endometrium throughout the menstrual cyde. J Endocrinol 1996; 148: 95-102.
18. Cullinan EB, Abbondanzo SJ, Anderson PS, Pollard JW, Lessey BA, Stewart CL. Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. Proc Natl Acad Sci USA 1996; 93: 3115-20.
19. Cameron S, Critchely H, Baird D. Immunolocalisation of leukemia inhibitory factor in secretory endometrium after antiprogestins [abstract]. Prostaglandins and Other Locally Active Factors in Reproduction, 4th European Congress, Stockholm, Sweden; 1996: f5.
20. Kojima K, Kanzaki H, Iwai M, et al. Expression of leukemia inhibitory factor in human endometrium and placenta. Biol Reprod 1994; 50: 882-7.
21. Arici A, Engin O, Attar E, Olive DL. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. J Clin Endocrinol Metab 1995; 80: 1908-15.
22. Aghajanova L, Stavreus-Evers A, Nikas Y, Hovatta O, Landgren BM. Coexpression of pinopodes and leukemia inhibitory factor, as well as its receptor, in human endometrium. Fertil Steril 2003; 79(Suppl 1): 808-14.
23. Guo X, Cheng Q, Wang Y. [Expression of endometrial leukaemia inhibitory factor gene in patients with unexplained infertility]. [Chinese] Chung-Hua Fu Chan Ko Tsa Chih. Chinese J Obstet Gynecol 2001; 36: 82-4.
24. Laird SM, Tuckerman EM, Dalton CF, Dunphy BC, Li TC, Zhang X. The production of leukaemia inhibitory factor by human endometrium: presence in uterine flushings and production by cells in culture. Hum Reprod 1997; 12: 569-74.
25. Delage G, Moreau JF, Taupin JL, et al. In vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. Hum Reprod 1995; 10: 2483-8.
26. Hambartsoumian E. Endometrial leukemia inhibitory factor (LIF) as a possible cause of unexplained infertility and multiple failures of implantation. Am J Reprod Immunol 1998; 39: 137-43.
27. Lédée-Bataille N, Laprée-Delage G, Taupin JL, Dubanchet S, Frydman R, Chaouat G. Concentration of leukaemia inhibitory factor (LIF) in uterine flushing fluid is highly predictive of embryo implantation. Hum Reprod 2002; 17: 213-8.
28. Olivennes F, Ledee-Bataille N, Samama M, et al. Assessment of leukemia inhibitory factor levels by uterine flushing at the time of egg retrieval does not adversely affect pregnancy rates with in vitro fertilization. Fertil Steril 2003; 79: 900-4.
29. Taupin JL, Gualde N, Moreau JF. A monoclonal antibody based ELISA for quantitation of human leukaemia inhibitory factor. Cytokine 1997; 9: 112-8.
30. Gearing DP, Nicola NA, Metcalf D, et al. Production of leukemia inhibitory factor in Escherichia coli by a novel procedure and its use in maintaining embryonic stem cells in culture. Bio/Technology 1989; 7: 1157-61.
31. Brinsden PR, Ndukwe G, Engrand P, et al. Does recombinant human leukaemia inhibitory factor improve implantation in women with recurrent failure of ART? [Abstract]. Hum Reprod 2003; 18(Suppl 1): O-050 Steril.
32. Boeckmann AJ, Sheiner LB, Beal S. Nonmem Users Guide-Part V. Introductory Guide November 1994: NONMEM Project Group. University of California, San Francisco, 1994.
33. Karlsson MO, Sheiner LB. The importance of modelling interoccasion variability in population pharmacokinetic analyses. J Pharmacokin Biopharm 1993; 21: 735-50.
34. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998; 15: 1463-8.